{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:59:20Z","timestamp":1772164760906,"version":"3.50.1"},"reference-count":22,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Eisai | Eisai Incorporated"}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>To determine a recommended dose of liposomal eribulin (E7389-LF) in combination with nivolumab in patients with advanced solid tumors, and to evaluate the safety, efficacy, pharmacokinetics, and biomarker impact of this regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Experimental Design:<\/jats:title>\n                    <jats:p>Japanese patients with advanced, nonresectable, or recurrent solid tumors and no existing alternative standard\/effective therapy (except nivolumab monotherapy) were assigned to either E7389-LF 1.7 mg\/m2 plus nivolumab 360 mg every 3 weeks, E7389-LF 2.1 mg\/m2 plus nivolumab 360 mg every 3 weeks, E7389-LF 1.1 mg\/m2 plus nivolumab 240 mg every 2 weeks, or E7389-LF 1.4 mg\/m2 plus nivolumab 240 mg every 2 weeks. Primary objectives were to evaluate the safety\/tolerability of each dose cohort and to determine the recommended phase II dose (RP2D). Secondary\/exploratory objectives, including safety [dose-limiting toxicities (DLT) and adverse events (AE)], pharmacokinetics, efficacy [including objective response rate (ORR)], and biomarker results were used in determining the RP2D.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-five patients were enrolled to treatment [E7389-LF 1.7 mg\/mg2 every 3 weeks (n = 6), E7389-LF 2.1 mg\/m2 every 3 weeks (n = 6), E7389-LF 1.1 mg\/m2 every 2 weeks (n = 7), E7389-LF 1.4 mg\/m2 every 2 weeks (n = 6)]. Twenty-four patients were evaluated for DLTs, of whom 3 had DLTs (1 at E7389-LF 1.7 mg\/m2 every 3 weeks, 1 at 1.1 mg\/m2 every 2 weeks, and 1 at 1.4 mg\/m2 every 2 weeks). All patients had \u22651 treatment-related treatment-emergent AE (TEAE); 68.0% had \u22651 grade 3\u20134 treatment-related TEAE. Changes in vasculature and IFN-related biomarkers were seen in each cohort. The overall ORR was 16%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>E7389-LF plus nivolumab was tolerable overall; the recommended dose for future study was 2.1 mg\/m2 plus nivolumab 360 mg every 3 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This phase Ib part of a phase Ib\/II study assessed the tolerability and activity of a liposomal formulation of eribulin (E7389-LF) plus nivolumab in 25 patients with advanced solid tumors. The combination was tolerable overall; 4 patients had a partial response. Vasculature and immune-related biomarker levels increased, suggesting vascular remodeling.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0401","type":"journal-article","created":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T10:05:31Z","timestamp":1686823531000},"page":"1189-1199","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Phase Ib\/II Study of a Liposomal Formulation of Eribulin (E7389-LF) plus Nivolumab in Patients with Advanced Solid Tumors: Results from Phase Ib"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-7143","authenticated-orcid":true,"given":"Hanae","family":"Ida","sequence":"first","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6632-0638","authenticated-orcid":true,"given":"Toshio","family":"Shimizu","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5543-6379","authenticated-orcid":true,"given":"Makoto","family":"Nishino","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-6855","authenticated-orcid":true,"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"2Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6141-9927","authenticated-orcid":true,"given":"Shu","family":"Yazaki","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."},{"name":"3Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2127-3601","authenticated-orcid":true,"given":"Yuki","family":"Katsuya","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9249-6522","authenticated-orcid":true,"given":"Jun","family":"Sato","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5807-8458","authenticated-orcid":true,"given":"Takafumi","family":"Koyama","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3863-9582","authenticated-orcid":true,"given":"Satoru","family":"Iwasa","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."},{"name":"4Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4600-9428","authenticated-orcid":true,"given":"Kazuki","family":"Sudo","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."},{"name":"3Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9565-117X","authenticated-orcid":true,"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."},{"name":"5Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7624-7611","authenticated-orcid":true,"given":"Kan","family":"Yonemori","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."},{"name":"3Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5196-3630","authenticated-orcid":true,"given":"Kohei","family":"Shitara","sequence":"additional","affiliation":[{"name":"2Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan."},{"name":"6Department of Immunology, Nagoya University Graduate School of Medicine, Nagoya, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0350-1195","authenticated-orcid":true,"given":"Satoshi","family":"Shiono","sequence":"additional","affiliation":[{"name":"7Oncology Early Clinical Operation II, Ono Pharmaceutical Co., Ltd., Osaka, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8250-7603","authenticated-orcid":true,"given":"Daiko","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"8Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8324-272X","authenticated-orcid":true,"given":"Keisuke","family":"Yasuda","sequence":"additional","affiliation":[{"name":"8Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5056-403X","authenticated-orcid":true,"given":"Yohei","family":"Otake","sequence":"additional","affiliation":[{"name":"8Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7692-9447","authenticated-orcid":true,"given":"Takuya","family":"Suzuki","sequence":"additional","affiliation":[{"name":"8Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4556-5035","authenticated-orcid":true,"given":"Takao","family":"Takase","sequence":"additional","affiliation":[{"name":"9Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7148-9250","authenticated-orcid":true,"given":"Shuya","family":"Takashima","sequence":"additional","affiliation":[{"name":"9Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5745-4773","authenticated-orcid":true,"given":"Kohei","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"10Clinical Pharmacology Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0432-1138","authenticated-orcid":true,"given":"Taro","family":"Semba","sequence":"additional","affiliation":[{"name":"11Oncology Tsukuba Research Department, Oncology Business Group, Eisai Co., Ltd., Ibaraki, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2851","authenticated-orcid":true,"given":"Noboru","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"1Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan."},{"name":"12Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"2023071014005702300_bib1","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"2023071014005702300_bib2","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/cas.13392","article-title":"Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models","volume":"108","author":"Ito","year":"2017","journal-title":"Cancer Sci"},{"key":"2023071014005702300_bib3","doi-asserted-by":"crossref","first-page":"Abstract nr 4089","DOI":"10.1158\/1538-7445.AM2019-4089","article-title":"Antitumor activity of eribulin in combination with anti-PD1 antibody in a mouse syngeneic breast cancer model [abstract]","volume":"79","author":"Semba","year":"2019","journal-title":"Cancer Res"},{"key":"2023071014005702300_bib4","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0140-6736(11)60070-6","article-title":"Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes","year":"2011","journal-title":"Lancet"},{"key":"2023071014005702300_bib5","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(15)01283-0","article-title":"Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial","volume":"387","author":"Sch\u00f6ffski","year":"2016","journal-title":"Lancet"},{"key":"2023071014005702300_bib6","doi-asserted-by":"crossref","first-page":"623760","DOI":"10.3389\/fonc.2021.623760","article-title":"Triggered drug release from liposomes: exploiting the outer and inner tumor environment","volume":"11","author":"Franco","year":"2021","journal-title":"Front Oncol"},{"key":"2023071014005702300_bib7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.3390\/pharmaceutics13040520","article-title":"Advances in lipid-based nanoparticles for cancer chemoimmunotherapy","volume":"13","author":"Wang","year":"2021","journal-title":"Pharmaceutics"},{"key":"2023071014005702300_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2013.01.010","article-title":"Characterization of the pharmacokinetics of a liposomal formulation of eribulin mesylate (E7389) in mice","volume":"443","author":"Yu","year":"2013","journal-title":"Int J Pharm"},{"key":"2023071014005702300_bib9","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41416-019-0377-x","article-title":"Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours","volume":"120","author":"Evans","year":"2019","journal-title":"Br J Cancer"},{"key":"2023071014005702300_bib10","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/1078-0432.CCR-21-3518","article-title":"Dose escalation data from the phase 1 study of the liposomal formulation of eribulin (E7389-LF) in Japanese patients with advanced solid tumors","volume":"28","author":"Sato","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2023071014005702300_bib11","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2022.03.004","article-title":"Phase 1 study of the liposomal formulation of eribulin (E7389-LF): results from the breast cancer expansion cohort","volume":"168","author":"Masuda","year":"2022","journal-title":"Eur J Cancer"},{"key":"2023071014005702300_bib12","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/cam4.4996","article-title":"Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer","volume":"12","author":"Udagawa","year":"2023","journal-title":"Cancer Med"},{"key":"2023071014005702300_bib13","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"2023071014005702300_bib14","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.1002\/jcp.29371","article-title":"The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"235","author":"Wang","year":"2020","journal-title":"J Cell Physiol"},{"key":"2023071014005702300_bib15","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci"},{"key":"2023071014005702300_bib16","article-title":"Opdivo\u00ae (nivolumab) [prescribing information]","author":"FDA","year":"2022"},{"key":"2023071014005702300_bib17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"key":"2023071014005702300_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"2023071014005702300_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.MCT-22-0475","article-title":"Liposome-encapsulated eribulin shows enhanced antitumor activity over eribulin for combination therapy with anti-PD-1 antibody","volume":"22","author":"Niwa","year":"2023","journal-title":"Mol Cancer Ther"},{"key":"2023071014005702300_bib20","doi-asserted-by":"crossref","first-page":"5461","DOI":"10.1158\/1078-0432.CCR-15-2839","article-title":"Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma","volume":"22","author":"Choueiri","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2023071014005702300_bib21","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1634\/theoncologist.2019-0284","article-title":"A phase I\/II open-label study of nivolumab in previously treated advanced or recurrent nasopharyngeal carcinoma and other solid tumors","volume":"24","author":"Ma","year":"2019","journal-title":"Oncologist"},{"key":"2023071014005702300_bib22","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/cas.14252","article-title":"Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg\/kg Q2W regimen in Japanese patients with advanced cancers","volume":"111","author":"Bei","year":"2020","journal-title":"Cancer Sci"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0401\/3340216\/crc-22-0401.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/7\/1189\/3346003\/crc-22-0401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/7\/1189\/3346003\/crc-22-0401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T10:40:47Z","timestamp":1688985647000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/7\/1189\/727673\/Phase-Ib-II-Study-of-a-Liposomal-Formulation-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,10]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,10]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0401","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.23654044","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654068","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654062.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523740.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523734","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523746.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654068.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654035.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654041.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654041","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654065","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654047.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523731","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523737.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654050.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523725.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654026","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523734.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523719.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654074","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654056.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523728","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654050","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654026.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654074.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654047","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523749","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523725","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523728.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654056","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654065.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654032","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523746","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523722","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523743.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654029.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654077","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523749.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523719","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654032.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654053","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654038.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523743","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523722.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654053.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654044.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654059.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654038","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523731.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654062","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523716","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523716.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654077.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523740","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654071.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654059","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654035","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523737","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.23523731.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654059.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654053.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523743","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523716.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654038.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523737.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654053","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523716","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654077","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6698165.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654029","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523749.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523746","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523722","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654074.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523743.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654032","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523719","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654056","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654065.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523725.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523737","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654035","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654047.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654059","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654041.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654032.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523740","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654062","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6698165.v2","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654029.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654038","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523719.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654056.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523731","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654041","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523734.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523728","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654065","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654050.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523746.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523734","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654068.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523740.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654044","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654068","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654077.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654071.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654062.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523725","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654071","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654044.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523728.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654047","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523722.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654026.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654035.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6698165","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654050","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654074","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23523749","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.23654026","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,10]]}}}